Proactive Investors - Run By Investors For Investors

Allergy Therapeutics outperforming the market "significantly" in latest financial year

Allergy Therapeutics plc's (LON:AGY) Nick Wykeman and Manuel Llobet tell Proactive the company has continued to take market share and is "outperforming the market significantly" as the firm releases its figures for the latest financial year.

The group said the year to the end of June was one of strong progress made against its strategic objectives of expanding in Europe, preparing for entry into the US market, and making clinical progress with the group's lead assets.

Despite a low pollen season, revenue rose 6.6% to £68.3mln from £64.1mln the year before, albeit helped by currency movements; on a constant currency (CC) basis, revenue growth was 3.5%.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use